Russian startup attracts $1.2 million to develop AI-powered diagnostics and disease risk assessment tools
Summary
The money was injected by two medtech investors: investment holding Tashir Medica and RVC-backed Unicorn Capital Partners. The Botkin.AI solution has excellent prospects for scaling in local and international markets,” said Tashir Medica Managing Partner Arsen Galstyan. According to Botkin.AI founder Sergey Sorokin, it only takes from several seconds to a few minutes for the patented Botkin.AI technology to analyze the images and diagnose lung cancer and pneumonia with extreme accuracy. If deployed at a large scale, it may even contribute to “decreasing mortality, including for patients with malignant neoplasms.” Earlier this year two Botkin.AI team members, Ivan Drokin and Elena Ericheva, won the “Best Paper” award in the computer vision track at the 9th International Conference on Analysis of Images, Social Networks, and Texts. The paper was about “Deep Learning on Point Clouds for False Positive Reduction at Nodule Detection in Chest CT Scans.”